Mitchell Charles L, Kurouski Dmitry
Interdisciplinary Program in Genetics and Genomics, Texas A&M University, College Station, TX, United States.
Department of Biochemistry and Biophysics, Texas A&M University, College Station, TX, United States.
Front Mol Neurosci. 2024 Aug 9;17:1431079. doi: 10.3389/fnmol.2024.1431079. eCollection 2024.
An unprecedented extension of life expectancy observed during the past century drastically increased the number of patients diagnosed with Parkinson's diseases (PD) worldwide. Estimated costs of PD alone reached $52 billion per year, making effective neuroprotective treatments an urgent and unmet need. Current treatments of both AD and PD focus on mitigating the symptoms associated with these pathologies and are not neuroprotective. In this review, we discuss the most advanced therapeutic strategies that can be used to treat PD. We also critically review the shift of the therapeutic paradigm from a small molecule-based inhibition of protein aggregation to the utilization of natural degradation pathways and immune cells that are capable of degrading toxic amyloid deposits in the brain of PD patients.
在过去一个世纪中观察到的预期寿命前所未有的延长,极大地增加了全球被诊断患有帕金森病(PD)的患者数量。仅帕金森病的估计每年花费就达到520亿美元,这使得有效的神经保护治疗成为一项紧迫且未得到满足的需求。目前针对阿尔茨海默病(AD)和帕金森病的治疗都集中在减轻与这些病症相关的症状上,而不具有神经保护作用。在这篇综述中,我们讨论了可用于治疗帕金森病的最先进治疗策略。我们还批判性地回顾了治疗范式从基于小分子抑制蛋白质聚集向利用能够降解帕金森病患者大脑中有毒淀粉样沉积物的天然降解途径和免疫细胞的转变。